anti-AAV9, human chimeric, ADK9-h1
Dot blot analysis of AAV1-AAV9, AAVrh10, AAVrh74, AAVDJ native (1E+09-1E+10 capsids) and denatured (1E+10 capsids, denatured at 95°C for 10 min in sample buffer) capsids.
The nitrocellulose membrane was blocked with 5% milk in PBST for 45 min at RT. The primary antibody anti-AAV9, human chimeric, ADK9-h1 (Cat. No. 692378) was diluted in blocking buffer (antibody concentration 100 ng/ml) and incubated for 1.5 h at RT. The secondary antibody anti-human IgG goat polyclonal, HRP conjugate was also diluted in blocking buffer (antibody concentration 200 ng/ml) and incubated for 1 h at RT. The bands were visualized by chemiluminescent detection using Pierce™ ECL Western Blotting Substrate.
Neutralization of AAV9 with mouse monoclonal AAV9 antibody clone ADK9 (A) and human chimeric AAV9 antibody clone ADK9-h1 (B) by using AAV9-NanoLuc® viral particles from Promega. (A) anti-AAV9 (intact particle) mouse monoclonal, ADK9 (Cat. No. 610162) or (B) anti-AAV9, human chimeric, ADK9-h1 (Cat. No. 692378) were preincubated with AAV9-NanoLuc® viral particles for 30 min at RT at 300 rpm (antibody concentrations 0.2-3,000 ng/ml). HEK293 cells (100 µl) were plated at 200,000 cells/ml in DMEM + 1% FCS. Virus-antibody-mix (20 µl) was added to the cells and incubated for 16-24 h at 37°C. Extracellular NanoLuc Inhibitor and Nano-Glo® Live Cell Assay System (Promega) was added to the wells and incubated for 5 min at RT at 300 rpm. Luminescence was measured using an ID5-Reader and plotted with Softmax Pro 7.1 software to determine the EC50 values.
View more
Dot blot analysis of AAV9 native (1E+09-1E+10 capsids) and denatured (1E+10 capsids, denatured at 95°C for 10 min in sample buffer) capsids with mouse monoclonal AAV9 antibody clone ADK9 and human chimeric AAV9 antibody clone ADK9-h1. The nitrocellulose membrane was blocked with 5% milk in PBST for 45 min at RT. The primary antibody anti-AAV9 (intact particle) mouse monoclonal, ADK9 (Cat. No. 690162) or anti-AAV9, human chimeric, ADK9-h1 (Cat. No. 692378) was diluted in blocking buffer (antibody concentration 100 ng/ml) and incubated for 1.5 h at RT. The secondary antibody anti-mouse IgA goat polyclonal, HRP conjugate or anti-human IgG goat polyclonal, HRP conjugate was also diluted in blocking buffer (antibody concentration 200 ng/ml) and incubated for 1.5 h at RT. The bands were visualized by chemiluminescent detection using Pierce™ ECL Western Blotting Substrate.
Comparison of binding affinity and neutralization activity of anti-AAV9 antibodies (mouse monoclonal ADK9, mouse recombinant ADK9-1R and human chimeric ADK9-h1).
View more
Dot blot analysis of AAV1-AAV9, AAVrh10, AAVrh74, AAVDJ native (1E+09-1E+10 capsids) and denatured (1E+10 capsids, denatured at 95°C for 10 min in sample buffer) capsids.
The nitrocellulose membrane was blocked with 5% milk in PBST for 45 min at RT. The primary antibody anti-AAV9, human chimeric, ADK9-h1 (Cat. No. 692378) was diluted in blocking buffer (antibody concentration 100 ng/ml) and incubated for 1.5 h at RT. The secondary antibody anti-human IgG goat polyclonal, HRP conjugate was also diluted in blocking buffer (antibody concentration 200 ng/ml) and incubated for 1 h at RT. The bands were visualized by chemiluminescent detection using Pierce™ ECL Western Blotting Substrate.
Neutralization of AAV9 with mouse monoclonal AAV9 antibody clone ADK9 (A) and human chimeric AAV9 antibody clone ADK9-h1 (B) by using AAV9-NanoLuc® viral particles from Promega. (A) anti-AAV9 (intact particle) mouse monoclonal, ADK9 (Cat. No. 610162) or (B) anti-AAV9, human chimeric, ADK9-h1 (Cat. No. 692378) were preincubated with AAV9-NanoLuc® viral particles for 30 min at RT at 300 rpm (antibody concentrations 0.2-3,000 ng/ml). HEK293 cells (100 µl) were plated at 200,000 cells/ml in DMEM + 1% FCS. Virus-antibody-mix (20 µl) was added to the cells and incubated for 16-24 h at 37°C. Extracellular NanoLuc Inhibitor and Nano-Glo® Live Cell Assay System (Promega) was added to the wells and incubated for 5 min at RT at 300 rpm. Luminescence was measured using an ID5-Reader and plotted with Softmax Pro 7.1 software to determine the EC50 values.
Dot blot analysis of AAV9 native (1E+09-1E+10 capsids) and denatured (1E+10 capsids, denatured at 95°C for 10 min in sample buffer) capsids with mouse monoclonal AAV9 antibody clone ADK9 and human chimeric AAV9 antibody clone ADK9-h1. The nitrocellulose membrane was blocked with 5% milk in PBST for 45 min at RT. The primary antibody anti-AAV9 (intact particle) mouse monoclonal, ADK9 (Cat. No. 690162) or anti-AAV9, human chimeric, ADK9-h1 (Cat. No. 692378) was diluted in blocking buffer (antibody concentration 100 ng/ml) and incubated for 1.5 h at RT. The secondary antibody anti-mouse IgA goat polyclonal, HRP conjugate or anti-human IgG goat polyclonal, HRP conjugate was also diluted in blocking buffer (antibody concentration 200 ng/ml) and incubated for 1.5 h at RT. The bands were visualized by chemiluminescent detection using Pierce™ ECL Western Blotting Substrate.
Comparison of binding affinity and neutralization activity of anti-AAV9 antibodies (mouse monoclonal ADK9, mouse recombinant ADK9-1R and human chimeric ADK9-h1).
- Recombinant chimeric (human Fc region)
- Suitable for dot blot, neutralization assay and serology ELISA
- Reacts with AAV9 intact capsids
- Isotype: IgG1
Product description
| Quantity | 1 ml |
|---|---|
| Antibody Type | Monoclonal |
| Host | Recombinant chimeric (human Fc region) |
| Isotype | IgG1 |
| Conjugate | Unconjugated |
| Application | Dot blot, Neutralization assay, Serology ELISA |
| Purification | Affinity chromatography |
| Reactivity | AAV9 |
| No reactivity | AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV8, AAVDJ, AAVrh10, AAVrh74 |
| Storage | 2-8°C |
| Intended use | Research use only |
| Clone | ADK9-h1 |
| Immunogen | AAV9 capsids |
| Concentration | 50 µg/ml |
| Formulation | PBS, pH 7.4 with 0.09% sodium azide and 0.5% BSA |
| Binding affinity | KD value (AAV9) = 7.0E-11 M |
| Synonym | Adeno-associated virus 9; AAV-9 |
Applications
| Tested applications | Tested dilutions |
|---|---|
| Serology Assay | 0.1-0.4 µg/ml (1:125-1:500; AAV9 ELISA) |
| Dot Blot | 0.1 µg/ml (1:500; non-denaturing conditions) |
| Neutralization Assay | EC50 ~8 ng/ml (AAV9) - assay dependent |
Background
Our human chimeric AAV antibodies are derived from our mouse monoclonal AAV antibodies and are a combination of the mouse antigen binding region and a human Fc region. Therefore, it provides the well-known characteristics of the corresponding mouse monoclonal antibody (anti-AAV9, ADK9, Cat. No. 690162) like cross-reactivity and neutralization activity combined with a human Fc region allowing the use in an anti-human secondary antibody detection system.
Many humans in the general population have developed antibodies against AAV as a result of naturally acquired infections, which might affect efficacy and safety of the gene transfer using AAV vectors. Therefore, testing for pre-existing AAV antibodies in patient sera is an indispensable step for the selection of patients for AAV gene therapy clinical trials.
Our human chimeric AAV antibodies are close to the human derived samples, making them the ideal positive control for reproducible and comparable serological assays.
Limited Use Label License: Research Use Only
Product is exclusively owned to PROGEN Biotechnik GmbH. The use of these products for the development, manufacturing and sale of secondary products/derivatives which are based on the purchased products and/or which include the purchased product require a royalty based sub-license agreement.
Downloads
Q & A's
Customer Reviews
Login
Related Products
- Consists of fully assembled, empty AAV9 capsids
- Represents serotype-specific conformational epitopes
- Reliable positive control for ELISA
- Fully assembled, empty AAV9 capsids
- Serotype-specific conformational epitopes
- Reliable positive control for dot blot, western blot, ELISA
- Quality controlled for purity, AAV titer and filling grade
- Alignment to internal reference standard material
For US shipment, the packages are only sent out for delivery on Mondays and Tuesdays, in the EU from Monday until Wednesday.
- ELISA for quantitation of AAV9 capsids
- Detection of full and empty AAV9 capsids
- ADK9 antibody is used as capture and detection antibody
- get results in less than 2 hours and increase your daily sample throughput
- easy workflow & process integration
- same accuracy and reproducibility as the standard AAV9 Titration ELISA
- ADK9 antibody is used as capture and detection antibody
- Mouse monoclonal
- Suitable for ELISA, ICC/IF, IP and WB
- Reacts with VP1 of AAV1, AAV2, AAV3, AAV5, AAV6, AAV7, AAV8, AAV9 and AAVDJ
- Isotype: IgG2a
- Mouse monoclonal
- Suitable for affinity chromatography, dot blot, ICC/IF, IP and WB
- Reacts with denatured VP1, VP2, VP3 proteins of AAV1, 2, 3, 5, 6, 7, 8, 9, rh10, DJ
- Isotype: IgG1
- Rabbit polyclonal
- Suitable for ELISA, ICC/IF, IP and WB
- Reacts with AAV1, AAV2, AAV3, AAV5, AAV6, AAV7, AAV8, AAV9, AAVrh10, AAVDJ and AAVrh74, weakly with AAV4
- Strong affinity for denatured capsid proteins
- Weak affinity for native capsids
- Purified, liquid
- Mouse monoclonal
- Suitable for dot blot, ELISA, ICC and neutralization assay
- Reacts with AAV9 intact particles
- Isotype: IgA kappa
- Purified, lyophilized
- Recombinant antibody
- Suitable for dot blot, ELISA and neutralization assay
- Reacts with AAV9 intacts particles
- Isotype: mouse IgG1
- Recombinant chimeric (human Fc region)
- Suitable for dot blot, neutralization assay and serology ELISA
- Reacts with AAV9 intact capsids
- Isotype: IgG1
- Rapid lateral flow test for the detection of AAV9 capsids
- Semi-quantitative AAV titer determination in cell lysates and purified preparations
- Detection of full and empty AAV9 capsids
- Highly effective for the separation of full and empty AAV particles
- Designed for the purification of viruses (such as AAV)
- Useful to isolate different cell types and organelles
- Ready-made, sterile and endotoxin-tested solution of iodixanol